Peptide Biologix
Compound index
The atlas

Vasopressin (Arginine Vasopressin / ADH)

Arginine vasopressin (AVP, antidiuretic hormone, argipressin) is a hypothalamic-neurohypophyseal cyclic nonapeptide characterized by an intramolecular Cys1–Cys6 disulfide bridge, an aromatic Phe3 residue within the 20-membered ring, and a basic Arg8 residue in the amidated C-terminal tail that mediates signaling across V1a, V1b, and V2 G-protein-coupled receptors.

Watercolour seaweed study with undulating kelp blades and a small holdfast
Plate 37Vasopressin
Class V — Reproductive, Neurohypophyseal & Melanocortin Peptides
AA Sequence (Cyclic Cys1-Cys6) Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Regulatory & Compounding Status (April 2026)

Vasopressin is an FDA-approved prescription drug substance (marketed as Vasostrict and Pitressin). This monograph documents analytical, chromatographic, and receptor binding specifications strictly for in vitro and preclinical laboratory research.

Molecular Properties

Parameter Specification
Chemical Name Arginine Vasopressin / Antidiuretic Hormone (ADH) / Argipressin
Amino Acid Sequence Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (disulfide bridge: Cys1-Cys6)
Molecular Formula C46H65N15O12S2
Molecular Weight 1084.23 g/mol
CAS Number 113-79-1 (11000-17-2)
Chain Length 9 amino acids
Structure Type Cyclic nonapeptide (6-amino acid ring via disulfide bond + 3-amino acid C-terminal tail)

Physical Properties

Property Specification
Appearance White to off-white lyophilized powder
Solubility Soluble in water, dilute acetic acid, or saline at ≥1 mg/mL; pH 3.5–5.5
pH (1% solution) 3.5 – 5.5 (acidic for stability)
Hygroscopicity Moderate; desiccated storage required
Solution Stability Stable at 4°C for 7–10 days at pH 3.5–5.5; degrades at neutral/alkaline pH

Analytical Specifications

Test Parameter Method Acceptance Criteria
Purity RP-HPLC (C18 column, 220 nm) ≥98.0%
Molecular Identity ESI-MS or MALDI-TOF MS Confirmed [M+H]+ = 1084.23 ± 0.5 Da; disulfide bridge intact
Peptide Content Amino Acid Analysis ≥95%
Disulfide Bond Integrity Mass Spectrometry & Bioassay ≥98% (intact intramolecular Cys1-Cys6 bridge)
Endotoxin Level LAL Assay (USP <85>) <1.0 EU/mg
Acetate Content Ion Chromatography ≤5%
Water Content Karl Fischer Titration ≤5%

Storage Parameters

  • Lyophilized Storage: -20°C to -80°C, desiccated, protected from light
  • Reconstituted Storage: 2–8°C for up to 10 days at pH 3.5–5.5; -20°C for up to 3 months
  • Reconstitution Protocol: Add 1.0 mL sterile water or 0.1 M acetic acid to 1 mg vial; vortex gently for 30 seconds
  • Freeze-Thaw Cycles: Maximum 3 cycles; single-use aliquots recommended
  • Light Sensitivity: Moderate; store in amber vials and protect from direct light

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Application Concentration / Protocol Route / Media
In Vitro Cell Culture 1–1000 nM Direct addition to culture media
Rodent Models (Antidiuretic / Pressor) 0.1–5 μg/kg (antidiuretic); 0.5–10 μg/kg (pressor) Intravenous (IV), Subcutaneous (SC), or Intraperitoneal (IP)
Water Retention Studies (V2) 0.1–1 μg/kg Intravenous (IV) preferred
Vascular Studies (V1a) 1–10 μg/kg IV bolus
Behavioral/Stress Studies 0.5–5 μg/animal (intranasal); 0.1–1 μg/kg (IV) Intranasal or IV (30–60 min pre-testing)

Unit Conversion Note: USP activity is typically expressed as Units (U); 1 mg ≈ 400–500 USP units.

Key Research Studies

Year Study Focus Key Findings
1954 Structure elucidation and synthesis Du Vigneaud determined vasopressin structure; differs from oxytocin by 2 amino acids (positions 3 and 8); Cys1-Cys6 disulfide bridge essential for activity; synthesized with full biological potency
1992–1994 Receptor subtype cloning Identified three receptor subtypes: V1a (vascular smooth muscle, liver), V1b/V3 (pituitary corticotrophs), V2 (renal collecting duct); differential Kd values: V1a ~1 nM, V1b ~1.5 nM, V2 ~0.5 nM
2005 Central nervous system effects on social behavior Brain V1a receptor activation modulated social recognition, aggression, and pair bonding in rodent models; species-specific V1a receptor expression patterns correlated with monogamous vs. polygamous behavior
2010 Structure-activity relationships across receptor subtypes Position 8 (Arg) critical for V2 selectivity; position 3 (Phe) enhances V1 selectivity vs. oxytocin receptor; C-terminal Gly-NH2 absolutely required with removal reducing potency >1000-fold

Mechanism of Action

  • V1a Receptor (Vascular): Gq-coupled → PLC → IP3/DAG → Ca2+ mobilization → vascular smooth muscle contraction → vasoconstriction and blood pressure elevation.
  • V1b Receptor (Pituitary): Gq-coupled on anterior pituitary corticotrophs → ACTH release → modulation of HPA axis and stress response.
  • V2 Receptor (Renal): Gs-coupled on collecting duct principal cells → cAMP/PKA → aquaporin-2 insertion into apical membrane → water reabsorption (antidiuretic effect).
  • Central Nervous System Effects: Modulates social recognition, circadian rhythms, temperature regulation, and stress response; V1a receptors expressed in lateral septum, hippocampus, and amygdala.
  • Half-Life: 5–20 minutes (IV); metabolized by vasopressinases (aminopeptidases) in liver and kidney.

Receptor Selectivity Profile

Receptor Subtype G-Protein Coupling Primary Tissue Distribution Binding Affinity (Kd)
V1aR Gq → PLC → Ca2+ Vascular smooth muscle, liver, CNS 0.5 – 2 nM
V1bR (V3R) Gq → PLC → Ca2+ Anterior pituitary (corticotrophs), CNS 1 – 3 nM
V2R Gs → adenylyl cyclase → cAMP Kidney collecting duct, endothelium 0.3 – 1 nM
Oxytocin Receptor (OXTR) Gq → PLC → Ca2+ Uterus, mammary, CNS 50 – 500 nM (low affinity)

Quality Control Parameters

Test Method Acceptance Criteria
Appearance (visual) White to off-white powder; no aggregation or discoloration
Disulfide Bridge Confirmation ESI-MS shows intact cyclic structure; no reduced form detected
RP-HPLC (purity) Main peak ≥98.0%; no single impurity >0.5%
Biological Activity (USP) ≥400 USP units/mg (rat pressor assay)
Amino Acid Analysis Confirmed sequence with Arg at position 8

Comparative Structural Analysis

Arginine vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) differs from oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) solely at positions 3 (Phe3 vs. Ile3, conferring V1 receptor selectivity) and 8 (Arg8 vs. Leu8, conferring V2 receptor selectivity and antidiuretic activity), while the Cys1–Cys6 disulfide bridge and C-terminal Gly-NH2 are essential for biological activity across both hormones.

Primary Scientific References

  1. du Vigneaud V, Lawler HC, Popenoe EA. Enzymatic cleavage of glycinamide from vasopressin and a proposed structure for this pressor-antidiuretic hormone of the posterior pituitary. J Biol Chem. 1953;205(2):949-957. JBC Reference
  2. Thibonnier M, Coles P, Thibonnier A, Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol. 2001;41:175-202. DOI: 10.1146/annurev.pharmtox.41.1.175
  3. National Center for Biotechnology Information. PubChem Compound Summary for Vasopressin. PubChem: Vasopressin